Released Nov 9, 2026, before the open
10-Q filed Nov 9, 2026, 40 days after period end · 0001171843-26-007258
What the release said
On November 9, 2026, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter and nine months ended September 30, 2026.
Compass reported a net loss of $27.2 million, or $0.15 per common share, for the quarter ended September 30, 2026, compared with $14.3 million, or $0.08 per share, for the same period in 2025.¶2
Research and development expenses were $22.0 million for the quarter, up from $12.8 million, primarily driven by $8.6 million of manufacturing costs related to tovecimig.¶3
General and administrative expenses were $6.8 million for the quarter, compared with $3.0 million a year earlier, including $1.5 million of pre-commercialization expenses.¶4
Cash and marketable securities were $163 million as of September 30, 2026, which the company expects will fund operations into 2028.¶5¶6
In September 2026, the FDA recommended an additional study demonstrating a survival benefit before a BLA submission, and Compass does not believe a new trial is warranted before submitting a BLA.¶7
- Net loss, three months ended September 30, 2026
- $27.2 million Compared with $14.3 million for the same period in 2025¶2
- Net loss per share, three months ended September 30, 2026
- $0.15 Compared with $0.08 per common share for the same period in 2025¶2
- Net loss, nine months ended September 30, 2026
- $70.6 million Compared with $50.8 million for the same period in 2025¶2
- R&D expenses, three months ended September 30, 2026
- $22.0 million Compared with $12.8 million for the same period in 2025, an increase of $9.2 million or 72%¶3
- G&A expenses, three months ended September 30, 2026
- $6.8 million Compared with $3.0 million for the same period in 2025, an increase of $3.8 million or 126%¶4
- Cash and marketable securities, September 30, 2026
- $163 million Compared with $209 million as of December 31, 2025¶6
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 |
| Net Income | -$27.17M | -$14.26M | -$10.48M | -$9.96M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR